These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 30545832)
21. Life after hypomethylating agents in myelodysplastic syndrome: new strategies. Santini V Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477 [TBL] [Abstract][Full Text] [Related]
22. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585 [TBL] [Abstract][Full Text] [Related]
23. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797 [TBL] [Abstract][Full Text] [Related]
24. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes. Komrokji RS Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741 [TBL] [Abstract][Full Text] [Related]
25. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Bewersdorf JP; Zeidan AM Expert Rev Hematol; 2020 Oct; 13(10):1131-1142. PubMed ID: 32876498 [TBL] [Abstract][Full Text] [Related]
26. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents? Sohn SK; Moon JH Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925 [TBL] [Abstract][Full Text] [Related]
27. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome. Ishikawa T Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411 [TBL] [Abstract][Full Text] [Related]
28. [Mechanism and Its Countermeasure of Hypomethylating Agent Resistance in Patients with Myelodysplastic Syndrome--Review]. Pang YB; Fan LX; Xue H; Liu J; DU X; Hua LM; Wang J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1574-1578. PubMed ID: 30295287 [TBL] [Abstract][Full Text] [Related]
29. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Zeidan AM; Klink AJ; McGuire M; Feinberg B Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526 [TBL] [Abstract][Full Text] [Related]
30. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Zeidan AM; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Podoltsev NA; Gore SD; Ma X; Davidoff AJ Leuk Lymphoma; 2019 Dec; 60(13):3181-3187. PubMed ID: 31170846 [TBL] [Abstract][Full Text] [Related]
31. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617 [TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
33. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes. Komrokji RS Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322 [TBL] [Abstract][Full Text] [Related]
34. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. Roberts DA; Steensma DP Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600 [TBL] [Abstract][Full Text] [Related]
35. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Ball B; Zeidan A; Gore SD; Prebet T Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579 [TBL] [Abstract][Full Text] [Related]
36. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990 [TBL] [Abstract][Full Text] [Related]
37. Making the most of hypomethylating agents in myelodysplastic syndrome. Bhatt G; Blum W Curr Opin Hematol; 2017 Mar; 24(2):79-88. PubMed ID: 28099273 [TBL] [Abstract][Full Text] [Related]
38. [Hypomethylating agents for the treatment of myelodysplastic syndromes]. Itzykson R; Fenaux P Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482 [TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108 [TBL] [Abstract][Full Text] [Related]